Florida-based biotech with approved cardiovascular therapy moves to go public via SPAC
A small commercial-stage biotech with one approved therapy for a rare disease that causes high cholesterol is hoping to go public through a SPAC deal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
